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Cardiovascular MRI in clinical trials: expanded
applications through novel surrogate endpoints
Alex Pitcher,1 Deborah Ashby,2 Paul Elliott,3 Steffen E Petersen4
ABSTRACT
Recent advances in cardiovascular magnetic resonance
(CMR) now allow the accurate and reproducible
measurement of many aspects of cardiac and vascular
structure and function, with prognostic data emerging for
several key imaging biomarkers. These biomarkers are
increasingly used in the evaluation of new drugs, devices
and lifestyle modifications for the prevention and
treatment of cardiovascular disease. This review outlines
a conceptual framework for the application of imaging
biomarkers to clinical trials, highlights several important
CMR techniques which are in use in randomised studies,
and reviews certain aspects of trial design, conduct and
interpretation in relation to the use of CMR.
INTRODUCTION
The randomised controlled trial (RCT) is the gold
standard approach to the evaluation of a new
proposed therapy for cardiovascular disease.1 2 The
growth in the number and scale of RCTs is in part
a consequence of the growth in candidate drug
targets, driven by new technologies for drug
discovery and screening and by a need to test
established therapies in new groups of patients.
Cardiovascular magnetic resonance (CMR) offers
a range of powerful imaging3 and spectroscopic4
techniques which can be used to identify suitable
participants for entry into trials, to ensure baseline
comparability of treatment arms and to generate
markers of disease presence, severity or activity for
use as outcome measures in clinical trials. Many of
these CMR-derived markers have been vali-
dated,5e14 and increasingly have been shown to be
closely linked to important clinical endpoints.15
These developments have led to a rapid increase in
their use in clinical trials, a trend which is likely to
continue. The versatility of CMR arises from the
wide range of sequences available, but only
a limited number can reasonably be applied to one
individual during a CMR study lasting perhaps
60 min. Each technique differs in terms of its
accuracy, precision, reproducibility, sensitivity, link
with clinical endpoints and ease of use in terms of
both acquisition and analysis. Trialists must there-
fore understand these characteristics for each
outcome measure selected.
The development and evaluation of a potential
new therapy is a complex process which varies
substantially in terms of time, costs and difficulty,
depending on the target condition and the therapy
proposed. CMR may have a role in several of the
four phases of drug or device development: to
identify suitable participants for enrolment and to
confirm baseline distribution of key prognostic
factors in different treatment arms at any phase of
treatment evaluation; to establish efficacy in phase
II and III studies, where it may be used to inform
a large-scale RCT of ‘hard’ clinical outcomes; to
extend the application of a proven therapy to other
groups of patients.
Reconciling the expanding pool of candidate
therapies and indications for treatment with the
desire to have the best possible evidence for efficacy,
safety and clinical effectiveness represents a signifi-
cant challenge.16 One approach is to accept only
hard clinical outcome-driven studies, accepting that
the resources required to do this mean that only
a small number of particularly promising therapies
will be evaluated. In this model, CMR may have an
important role in identifying the most promising
therapies for further evaluation. A second approach
is to broaden the scope of therapies but to evaluate
them in restricted patient groups, commonly high-
risk groups (who are most likely to experience
clinical events). Here, CMR may have a role in
confirming efficacy in wider patient groups. A third
approach has been to measure a circulating
biomarker which is linked to disease severity and to
assume that, if the biomarker moves in a direction
thought to be advantageous, this will correspond to
a consequent reduction in clinically meaningful
endpoints.17 While such studies may be useful in
demonstrating efficacy, recent high-profile studies
highlight the risks inherent in assuming that
a single circulating biomarker can adequately
capture all of the relevant consequences of manip-
ulating a complex biological system.18 For example,
in the ILLUMINATE study19 the CETP inhibitor
torcetrapib was shown to worsen clinical outcome
despite a theoretically favourable direction of
movement of circulating biomarkers. CMR and
other imaging modalities may have an intermediate
role between early studies showing potential
benefit in single biomarkers and large-scale RCTs
using clinical outcomes. It is of interest that two
imaging studies of torcetrapib (RADIANCE 120 and
ILLUSTRATE21) did not demonstrate plaque
regression. The advantage of imaging surrogate
endpoints over circulating surrogate biomarkers is
that they capture the downstream activation or
common final pathway of disease progression,
whereas circulating biomarkers may interrogate
a single pathway which may be only one of many
relevant pathways. Imaging surrogate endpoint
studies can have an important (though not exclu-
sive) role in the evaluation of potential therapies
taking place after animal and human dose-ranging
studies (phase IeII) but before (and generally as
a supplement to or screening process for) large-scale
randomised trials. In such cases, it may be that
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CMR can reliably discriminate clinically important treatment
differences with smaller sample sizes than less precise
biomarkers, and hence provide results more rapidly and at
a potentially lower overall cost than other surrogate endpoints.
In all cases, good pharmacovigilance practice will continue to be
of great importance.22
DEFINITION OF TERMS
The Biomarkers Definitions Working Group of the US National
Institutes of Health defines a biomarker as a characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathological processes or pharmacological
responses to a therapeutic intervention.23 Surrogate endpoints are
those biomarkers which are intended to substitute for clinical
endpoints in clinical research studies and, as such, are expected to
predict clinical benefit (or harm) based on epidemiological, ther-
apeutic, pathophysiological or other scientific evidence. The
distinction between biomarker and surrogate endpoints is
important, emphasising that only a proportion of biomarkers can
be regarded as surrogate endpointsdnamely, those that can
predict clinical outcomes. The Working Group definition draws
a distinction between biomarker (or surrogate endpoint) for
efficacy and biomarker (or surrogate endpoint) for toxicity,
usually safety. Imaging endpoints such as those acquired using
CMR are predominantly endpoints for efficacy, and there has
been a concerted effort within the field in recent years to link
imaging biomarkers to clinical outcomes, and these will be
augmented by ongoing and future large-scale longitudinal studies.
SURROGATE ENDPOINTS
The essential feature of a surrogate endpoint is its sensitivity.
Clinical events are generally insensitive markers of disease
activity because clinical events are generally rare and so typically
require large numbers of individuals to be followed for
protracted periods. Surrogate endpoints are more sensitive
markers of disease presence, severity or activity, are usually
continuous variables, and so are ‘common’ and therefore reduce
the sample sizes required to have a certain power to detect an
effect of given clinical and statistical significance. These reduc-
tions in sample size can often be translated into reduced cost and
duration of a trial compared with a study based on clinical
endpoints or trials using less precise surrogates. The use of
surrogate endpoints of all types has come under close scrutiny in
recent years. Historically, the CAST trials (in which flecainide
and encainide reduced arrhythmias after myocardial infarction
but increased mortality) were among the first to highlight the
possibility of discordance between the direction of movement of
a surrogate endpoint and clinical outcome.24 More recently, the
ILLUMINATE study19 showed no net benefit of treatment
(indeed, as noted above, it showed potential for harm), yet the
biomarker changes would have anticipated benefit. A limitation
of all surrogate endpoint studies is that even the best marker of
disease presence and activity provides only limited (if any)
information about the effects of the drug in question on organ
systems or processes which are not the target pathophysiolog-
ical process. These so-called off-target effects, such as liver
dysfunction or QT interval prolongation, are important and
need to be rigorously evaluated prior to the universal uptake of
such therapies (box 1).
CMR: A RANGE OF TECHNIQUES WHICH CAN GENERATE
IMAGING SURROGATE ENDPOINTS
In general, CMR as a technique has several strengths which
make it, for many applications, the imaging modality of choice
for assessing the cardiovascular phenotype. First, it provides
inter alia a versatile and sensitive assessment of many aspects of
cardiovascular structure and function; these include ventricular
function,25 valve function,10 vascular anatomy and function,8
determining the presence and extent of myocardial scar,5 eval-
uating myocardial perfusion26 27 and myocardial tissue charac-
teristics.28 29 Second, it is safe, well-tolerated, non-invasive and,
because no ionising radiation is used (unlike CT and nuclear
methods), it lends itself to studies making repeated measures of
the same individualdfor example, before-and-after treatment
phasesdwith potentially important reductions in sample size
(and hence cost) for a given power, statistical significance
threshold and predicted treatment effect size. Third, CMR
allows assessment of parameters that cannot easily be evaluated
in any other way and therefore provides a unique insight into
some aspects of cardiovascular disease processesdfor example,
T2 imaging for myocardial oedema30 and T2* imaging for the
assessment of myocardial iron overload.11 31 Fourth, there is now
a robust evidence base for the validation and reproducibility of
many CMR techniques and an emerging pool of data regarding
the prognostic implications of CMR surrogate endpoints.15
LIMITATIONS OF CMR FOR CLINICAL TRIALS
Several limitations must be considered when planning CMR
clinical trials. Implanted pacemakers, defibrillators and
resynchronisation devices generally preclude CMR imaging on
safety grounds, although strategies to reduce risk can be
employed in the clinical arena.32 This is an important limitation,
particularly for studies of patients with advanced cardiac disease
in whom treatment effects are perhaps easier to detect and for
whom new treatments are most likely to be of benefit.
Another barrier to CMR use in clinical trials is logistics. CMR
systems require major investment in hardware, software, infra-
structure and maintenance, and access is limited in many parts
of the world. The technique is complex and substantial training
and experience is required to allow accurate measurements.
There may be limited transferability of some sequences across
vendors, field strengths and even different sites using the same
system and field strength. Standardised protocols for data
acquisition and analysis, often with core-lab data analysis, are
essential in the clinical trial setting and these have been and are
being developed by the Society for CMR, along with a registry of
clinical trials involving CMR.33
CMR mandates a period of relative inaccessibility of the
participant while data are acquired and so cannot be performed
at certain times in a patient’s clinical care; this can limit its
usefulness in some types of study. An important example is
patients with ST elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI)
Box 1 Characteristics of an ideal surrogate imaging
endpoint
Accurate
Repeatable
Reproducible
Sensitive
Uniqueness
Prognostically important
Proven interventions lead to change in the surrogate endpoint
which translates into improved prognosis
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in whom it is clearly not feasible to perform CMR in the
immediate phase of admission prior to urgent reperfusion
therapy. This limits the use of before-and-after study designs for
the evaluation of new therapeutic adjuncts to primary angio-
plasty in STEMI. It should be noted, however, that safe imaging
of patients with recent myocardial infarction is highly feasible in
experienced units with careful safety planning and robust plans
for patient evacuation and resuscitation, and has been used in
a number of studies.
Optimal time point selection is an important aspect of the
application of CMR to clinical trials. Several CMR surrogate
endpoints of disease visualise and quantify a highly dynamic
process, such as the evolving extent of markers of myocardial
reversible and irreversible damage as scar and ventricle remodel
in the weeks following a myocardial infarction. This inherent
within-patient variability means that time point selection is
critical.
The strengths and weaknesses of CMR for clinical trials are
shown in box 2.
SELECTED CMR TECHNIQUES USED FOR CLINICAL TRIALS
A wide variety of CMR sequences, protocols and analysis tech-
niques are available to the trialist. Some of these approaches
generate surrogate markers which are widely accepted and some,
while validated, remain experimental in a clinical trial context
because the prognostic implications of the biomarker are
uncertain. The selection of a surrogate marker depends upon the
question under study and the way in which a trial will be
interpreted. We highlight here just three examples of categories
of parameters which can be measured and discuss the extent to
which they meet the criteria listed above for a good surrogate
marker. We also discuss limitations and give some examples of
their use in recent randomised trials.
VASCULAR IMAGING
Atherosclerosis is the leading cause of death in developed
countries, and emerging therapies will continue to focus on
disrupting the pathways which lead to the progression and
destabilisation of atherosclerotic plaque. CMR has recently been
used in a number of RCTs, and a role complementary to other
imaging modalities is emerging for clinical trials in atheroscle-
rosis.34 Quantitative coronary angiography, intravascular ultra-
sound, optical coherence tomography, carotid-intima media
thickness, CT and positron emission tomography all have
advantages in different settings, but the strength of CMR lies in
its ability to discern distinct plaque components non-invasively,
repeatably and with small sample sizes.
Atherosclerosis imaging by CMR can measure a number of
aspects of large artery (aorta and carotid) arterial wall structure
and function.35 The non-invasive nature of CMR allows serial
imaging of the same region of vasculature and the same plaque
over time without ionising radiation, although gadolinium-
based contrast agents are sometimes needed. Several measures
have now been standardised and can be routinely measured by
experienced core-labs: wall area and wall volume both measure
plaque volume whereas minimal lumen area and plaque eccen-
tricity measure degree of intrusion of the plaque into the lumen
and disposition of the plaque, respectively. These measures are
highly reproducible36 and agree closely with histological and ex
vivo magnetic resonance measures.37 38
Saam et al have provided reproducibility calculations for
several CMR atherosclerosis measures based on serial magnetic
resonance data from the placebo group of an RCT.39e41 Corti
et al used CMR to demonstrate reductions in vessel wall area and
vessel thickness in both the carotid and thoracic aorta over
24 months in an RCT of simvastatin in 18 individuals with
known atherosclerotic plaque.41 Lee et al 42 showed a decrease in
carotid wall area with modified-release nicotinic acid in 17
statin-treated patients over 12 months, several years before
large-scale clinical endpoint studies are scheduled to report.
A recent change of emphasis in atherosclerosis imaging is from
measures of plaque extent to attempts to evaluate the biological
activity or risk posed by a plaque, using techniques which
measure plaque composition or biological activity including
inflammation or markers of vascular elastic function. CMR can
assess the fibrous cap, the lipid-rich/necrotic core, the presence,
extent and age of intra-plaque haemorrhage and the relative
contribution of loose and dense fibrous tissue to the plaque.
AHA lesion classification, soft plaque identification and plaque
risk assessment may be achieved.43 The ORION study showed
regression of the lipid-rich necrotic core of carotid plaque using
rosuvastatin over 2 years,44 demonstrating that serial carotid
magnetic resonance could evaluate regression of individual
plaque components, with particular significance for a number of
emerging proposed therapies for atherosclerosis.
Current research efforts in CMR atherosclerosis imaging are
investigating putative markers of the biological activity of the
plaque, particularly with respect to inflammation. Ultra-small
superparamagnetic iron oxide (USPIO) particles injected intra-
venously may reflect macrophage activity, and the recent
ATHEROMA trial showed a reduction in USPIO accumulation
in carotid plaque in subjects randomised to high-dose compared
with low-dose atorvastatin.45 CMR can evaluate the functional
consequences of atheroma burden on the elastic function of
arteries and can measure both regional and global aortic stiff-
ness. Furthermore, the forces and shear stress acting on the wall
of the artery can now be measured. Low wall shear stress and
high oscillatory shear index have been linked to endothelial
activation.
At present, high resolution CMR arterial wall imaging and
plaque characterisation is available only for large, relatively
immobile arteries, and the walls of the coronary arteries in
particular cannot be assessed in this way owing to their small
size, mobility and tortuosity. While carotid and abdominal aortic
atheroma are of clinical relevance and probably broadly reflect
the overall atheroma burden, extrapolation of atheroma
Box 2 Strengths and weaknesses of cardiovascular
magnetic resonance for clinical trials
< Strengths
– Safe, non-invasive and repeatable
– Versatile
– Suitable for statistically powerful repeated measures and
crossover study designs
– Validation and reproducibility data for many measures
– Emerging prognostic data for some measures
< Weaknesses
– No implanted devices
– Complexity and need for specialist training
– Limitation for very acute studies (eg, new primary PCI
adjuncts)
– Dynamic nature of underlying processes (eg, infarct size
change) so time point selection important
– Lack of prognostic data for some measures
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regression at one site to other vascular beds may not always be
justified. In a study by Yonemura et al the reduction in plaque
volume seen in the carotid artery with high-dose atorvastatin
was not seen in the abdominal aorta.46
There is correlation between Framingham risk and CMR
markers of atherosclerosis,47 and small studies have suggested
that carotid CMR findings predict the subsequent risk of
stroke,48 49 but the predictive value of such imaging beyond
standard risk prediction scores has not yet been proven in large
longitudinal studies, although such studies are underway (box 3).
INFARCT SIZE BY LATE GADOLINIUM ENHANCEMENT (LGE)
The development of new therapies for the treatment of ongoing
or completed myocardial infarction is an important goal in
cardiovascular drug and device development. The improvements
in mortality and morbidity following myocardial infarction in
recent years mean that demonstrating a further reduction
requires large sample sizes. A number of CMR techniques are
now well established in the clinical evaluation of patients with
acute and chronic myocardial infarction and have been reviewed
recently.50e52 CMR affords a highly accurate means of quanti-
fying the size5 and transmural extent6 and anatomical location
of myocardial infarction (figure 1) and this, combined with
accurate measures of left ventricular volumes, systolic function,
wall thickness and wall thickening, allows the accurate charac-
terisation of the ‘severity ’ of myocardial infarction with much
greater sensitivity than clinical endpoints (even when these are
combined as composite endpoints). Infarct size is a powerful
predictor of subsequent clinical outcome,53 and recent studies
have reported that infarct size measured by LGE-CMR is
a stronger predictor of clinical outcome than left ventricular
ejection fraction or left ventricular volumes.54e56 LGE-CMR
may have advantages over nuclear techniques for the evaluation
of new therapies in some contexts. Specifically, the increased
sensitivity of CMR for subendocardial infarction of <50%
transmural extent in both acute57 and chronic infarction58 is
likely to reduce sample sizes. Kim et al have recently reviewed
the role of CMR in both the clinical management and in infarct
size measurement in clinical trials of myocardial infarction59 and
make several important points relevant to the use of this tech-
nique. First, infarct size evolves over the days and weeks
following a myocardial infarction so imaging studies are most
likely to be useful after 3 months post-infarct. Second, trans-
parency in reporting the time after the infarct is essential. Third,
serial imaging of infarct size is not feasible in many trials of
acute myocardial infarction because of the clinical condition of
the patient on arrival in hospital and the need for emergency
care; thus the advantage of high reproducibility of the technique
may be offset by the inability to acquire before-and-after treat-
ment imaging data. As a result, paired tests (before/after) may
not be possible and the large reductions in sample size seen in
some other contexts25 39 may not be realised. While this is true
for the evaluation of therapeutic interventions that need to be
instituted within minutes to hours (such as potential improve-
ments of primary PCI), it may be possible to achieve sequential
imaging where the treatment is to be administered subacutely
(eg, several hours to several days after admission) or with elec-
tive procedures (eg, coronary artery bypass graft or complex
PCI).60 61 Importantly, LGE used in a parallel (rather than
repeated measures) study design still requires only a fraction of
the sample size compared with other less reproducible tech-
niques. CMR methods were used to evaluate adjuncts to
primary PCI in the CE-MRI sub-study of the EXPIRA study,
showing reduced infarct size by LGE-CMR in patients rando-
mised to receive adjunctive thrombectomy using a manual
device during primary PCI for STEMI.62
VENTRICULAR VOLUMES, MASS AND FUNCTION
The ability of CMR to measure ventricular volumes, mass and
function accurately, reproducibly and on serial studies without
Box 3 Atherosclerosis imaging by cardiovascular
magnetic resonance
< Plaque anatomy
– Wall area
– Wall volume
< Plaque lumen effects
– Minimal lumen area
– Plaque eccentricity
< Wall composition
– Fibrous cap classification
– Lipid-rich/necrotic core
– Intra-plaque haemorrhage
– Dense/loose fibrous tissue
< Wall mechanics
– Compliance
– Distensibility
– Wall shear stress
– Oscillatory shear index
< Biological activity
– Inflammation
Figure 1 Late gadolinium
quantification. Inversion-recovery short
axis image of the left ventricle after
administration of a gadolinium-based
contrast agent showing (A) endocardial
and epicardial contours, definition of
a region of remote myocardium, and (B)
automated segmentation of infarcted
from non-infarcted myocardium (based
on >2SD pixel intensity compared with
remote myocardium).
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significant risk to the patient is a major strength of CMR for
clinical trials. Bellenger et al demonstrated substantial sample
size reductions (of 81e97%) if CMR measures of volumes, mass
and function were serially obtained compared with echocardi-
ography.25 The sample sizes required for left ventricular mass in
particular were small (n¼9 for each group to detect a 10 g
change in left ventricular mass with a power of 90% and p value
of <0.05), based on the high reproducibility of this measure by
CMR. This is of relevance to conditions in which ventricular
performance or responses are important such as hypertension.
Several recent studies have evaluated emerging therapies for
hypertension using left ventricular mass index as a primary
endpoint. The ALLAY study63 used a non-inferiority study
design to show that the direct renin inhibitor aliskirin was non-
inferior to losartan monotherapy in reducing left ventricular
mass index. The effect of the phosphate binding drug sevelamer
is currently being evaluated to determine its effects on left
ventricular mass in patients with early kidney disease,64
demonstrating that the current use of CMR endpoint studies is
not confined to therapies conventionally regarded as being
primarily used for cardiovascular indications. CMR may also
have a role as part of broader cardiovascular safety studies for
drugs intended to treat both cardiovascular and non-cardiovas-
cular conditions.
CURRENT USE OF CMR IN CLINICAL TRIALS
The number of clinical trials using CMR has grown rapidly in
recent years. We searched the NIH international trials register for
completed registered clinical intervention trials with at least one
endpoint including CMR using the search terms (cardiac OR
vascular OR cardiovascular) AND magnetic AND resonance.65
We excluded studies which were principally intended to evaluate
diagnostic performance of an imaging modality. Fifty-five studies
fitted these criteria with total enrolment of 5659 subjects. The
mean (SD) sample size was 105 (95) enrolled subjects; 24 studies
evaluated treatments for myocardial infarction and nine studies
evaluated atherosclerosis. A CMR endpoint was the primary
endpoint in 44 of the 55 studies and, in these studies, well-
established endpoints such as left ventricular volumes, mass or
function were used more frequently (23 studies) than less well-
established biomarkers such as USPIO-enhanced MRI signal in
carotid plaques (1 study). Unregistered trials and studies regis-
tered on other databases were not captured, so these figures
probably represent an underestimate of the use of CMR inter-
nationally for this type of study.
CLINICAL TRIAL PRINCIPLES FOR CMR
The increasing use of CMR for the clinical evaluation of new
therapies will require close collaboration between CMR practi-
tioners, pharmacologists, trialists, statisticians and the phar-
maceutical industry. Good practice regarding clinical trial design,
conduct, analysis and reporting is essential in CMR trials, and
training in these areas will be required for CMR practitioners
who are involved with clinical trials.
TRIAL DESIGN
CMR is well suited to a number of study designs (figure 2).
Crossover studies, in which each participant is randomly allo-
cated to a sequence of therapeutic arms, are particularly to be
Figure 2 Four different study designs.
Upper panels show crossover designs,
lower panels show parallel designs.
Panels on the left show single
cardiovascular magnetic resonance
(CMR) scan per treatment phase,
panels on the right show before/after
scans for each treatment phase.
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encouraged where the therapy in question is likely to have fairly
rapidly reversed effects on a long-term condition, in view of the
favourable effects of this design on sample size, for a given
power and level of statistical and clinical significance (figure 3).
TRIAL ANALYSIS
CMR sequences, protocols and endpoints should be prespecified
in the trial protocol, which should be registered and published.66
One endpoint should be specified as the primary endpoint. CMR
outcome assessment can often (but not always) be blinded to
treatment allocation. Artefacts related to treatment allocation
will sometimes compromise blinding of outcome asses-
smentdfor example, artefacts related to sternal wires in trials of
coronary artery bypass grafting versus medical therapy.67
TRIAL REPORTING
Clinical trials using CMR to evaluate an investigational medic-
inal product or other intervention should be reported and
considered for publication if they address an important clinical
question, with robust methods and are adequately powered,
regardless of the direction or magnitude of the study findings.68
CMR trials should adhere to CONSORT guidelines for clinical
trial reporting,69 and reports should pay particular attention to
the method of randomisation, allocation concealment and
blinding and should make clear which analyses and endpoints
were prespecified (and therefore hypothesis-testing) and which
were not (and therefore hypothesis-generating).
CONCLUSION
More than ever, the process of identifying promising therapies
and their evaluation from the laboratory to the clinic requires
collaboration between widely differing fields. The versatility and
power of CMR to address key issues in the evaluation of ther-
apies for many cardiovascular diseases means that close collab-
oration will be needed between CMR specialists and others
involved in clinical trials. This will ensure best use of the
opportunity which CMR affords to evaluate promising new
therapies and ultimately to deliver these therapies to patients
with cardiovascular disease.
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